LAVA Therapeutics NV

LAVA Therapeutics NV — Investor Presentation (June 2024)

28 slides from LAVA Therapeutics NV's investor presentation, Jun 6, 2024

  1. Slide 1: Gamma-delta T cell engagers for next-generation cancer therapeutics

    Gamma-delta T cell engagers for next-generation cancer therapeutics Investor Presentation June 2024 ©2024 LAVA Therapeutics. All rights reserved.

  2. Slide 2: Forward-looking statements

    2 This presentation contains statements that constitute forward-looking statements. Many of the forward-looking statements contained in this presentation can be identified by the use of forward-looking words such as “anticipate,” “believe,” “could,” “expect,” “should,” “plan,” “intend,” “estimate” a

  3. Slide 3: Investment Highlights

    3 Potential first-in-class Platform maximizing the unique anticancer potential of Gamma-Delta T cells1 Engineered to selectively activate V2 T cells upon cross-linking with tumor-associated antigen Designed to drive larger therapeutic window with low incidence of high-grade CRS and limited on-targe

  4. Slide 4: Gammabody Platform Pipeline: Potential in Hematologic Malignancies and Solid Tumors

    4 Gammabody® Platform Pipeline: Potential in Hematologic Malignancies and Solid Tumor Indications 1. LAVA announced a clinical collaboration with Merck & Co., on January 25, 2024 for LAVA-1207. PSMA: prostate-specific membrane antigen; EGFR: epidermal growth factor receptor; mCRPC: metastatic castra

  5. Slide 5: Gammabody Platform Overview

    Gammabody® Platform Overview

  6. Slide 6: LAVA's Bispecific T Cell Engager Strategy Focused on Recruiting Vδ2 T Cells

    6 LAVA’s Bispecific T Cell Engager Strategy is Focused on Recruiting V2-T Cells Therapeutic Window 1 st generation T cell engagers • CD3 (pan) T cell activators • High grade cytokine release syndrome (CRS) toxicities • On-target/off-tumor toxicities • Co-activation of Tregs • Sporadic efficacy in s

  7. Slide 7: Vδ2 T Cells

    7 Vδ2 T Cells Adapted from Dranoff G, Nature Rev Cancer 2004; 4: 11-22 Kabelitz D et al., Cell Mol Immunol 2020; 17: 925–939 Positioned at the interface between innate and adaptive immunity • Largest  T cell subset in blood: (~90-95% of total  T cells) • Natural ability to recognize and kill tum

  8. Slide 8: Selective Activation of Vδ2 T Cells Could Coordinate the Immune Response Against Tumors

    8 Selective Activation of Vδ2 T Cells has the Potential to Coordinate the Immune Response Against Tumors 1 Lameris R et al. Cell Reports Med 2023, Data on file, 2 King L, et al, Cancer Immunol Res 2023; 11:1237-1252​, 3 King L, et al. in preparation EXPANSION BROAD IMMUNE ACTIVATION ANTIGEN PRESENTA

  9. Slide 9: Sparing of Normal Tissue is a Key Differentiator of the Gammabody Platform

    9 Sparing of Normal Tissue is a Key Differentiator of the Gammabody® Platform1 Gammabody® Platform 1. In preclinical models, LAVA Therapeutics, data on file Prostate Cancer Normal Prostate *** p<0.001 PSMA Gammabody Mediated Killing1 • Potential for larger therapeutic window • Preferential killing o

  10. Slide 10: LAVA-1207 Targeting PSMA for mCRPC

    LAVA-1207 Gammabody Designed to Activate V2 T Cells by Targeting PSMA for the Treatment of mCRPC

  11. Slide 11: LAVA-1207 Targets PSMA: Enrolling in Phase 1/2a

    11 Highly-expressed in >90% prostate cancers1 .. Higher levels negatively correlated with survival2 FDA approval of Pluvicto, a PSMA-targeted radiopharmaceutical, provides clinical validation While early-stage outcomes are good, mCRPC prevalence is 50,000 in the U.S.3 With ~35,000 prostate-cancer re

  12. Slide 12: LAVA-1207 Phase 1/2a mCRPC Study Design

    12 LAVA-1207 Phase 1 mCRPC Study Design =3+3, AR = Androgen receptor Therapy refractory mCRPC Dosing: every 2 weeks Optional adjustments • Dose level • Dosing frequency • # cohorts Therapy refractory mCRPC Dose Escalation Dose Expansion GOAL Determine recommended dose and schedule based on optimal b

  13. Slide 13: LAVA-1207 Study Schema – Phase 1 Ongoing

    13 RP2D RP2D Dose Level 1-5 Dose Level 6 + LD IL-2 Dose Level 6 Dose Level 7 Dose Level 8 Dose Level 9 Dose Level 7 + LD IL-2 Addition of LD IL2 at cleared doses continued dose escalation to MTD/BAD Dose Level 10 Dose Level 8+ + LD IL-2 Addition of pembro at cleared doses Dose Level 11+ Dose Level X

  14. Slide 14: Why explore the combination of LAVA-1207 and PD-1 mAb

    14 Why explore the combination of LAVA-1207 and PD-1 mAb • PD-1 can be expressed by Vδ2-T cells (in patient Tumor-Infiltrating Lymphocyte (TIL), PBMC) and is upregulated after exposure to bispecific γδ-TCE – This has the potential to dampen the antitumor effect of LAVA-1207 (and could be released by

  15. Slide 15: Phase 1/2a Snapshot from ASCO GU 2023

    15 Median patient was 68 years old, had received 4 rounds of prior therapy and was median 9 years from diagnosis Metastases were primarily located in bone, lymph nodes and visceral tissues No occurrence of high-grade CRS (>2) No increase in severity/frequency of TEAEs (grade 1 and 2) with increasing

  16. Slide 16: ASCO GU 2023: Time on Treatment

    16 ASCO GU 2023: Time on Treatment Data cutoff: December 8, 2022, ASCO GU 2023 0 2 4 6 8 10 12 14 16 18 20 22 24 26 28 30 32 34 36 38 40 N307 N306 N105 - N305 N304 N303 - N104 N206 N302 - U105 U104 N205 N301 N202 - U103 U102 U101 N101 N102 N201 Time since first study treatment (weeks) DL 1 1.5 μg DL

  17. Slide 17: ASCO GU 2023: Best PSA Response

    17 ASCO GU 2023: Best PSA Response Data cutoff: December 8, 2022, ASCO GU 2023 PSA change from baseline (%) Subsequent to ASCO GU: • Continue to see PSA reductions and other signs of potential antitumor activity

  18. Slide 18: ASCO GU 2023: Initial Phase 1 Safety Data

    18 Data cutoff: December 8, 2022, ASCO GU 2023 • Favorable safety profile with no occurrence of high-grade (>2) CRS • TEAEs that were suspected to be related were grade 1 or 2 • No increase in severity or frequency of TEAEs with increasing doses • One grade 4 AE occurred (spinal cord compression, DL

  19. Slide 19: ASCO GU 2023: Pharmacokinetics and Pharmacodynamics

    19 ASCO GU 2023: Pharmacokinetics and Pharmacodynamics Data cutoff: December 8, 2022, ASCO GU 2023; EOI = end of infusion; Sbj = subject Continuing to see V2 T cell receptor occupancy with increasing doses 0 2 4 6 8 1 0 0 5 0 1 0 0 1 5 0 2 5 5 0 V γ 9Vδ 2 T ce lls - % o f CD 45 Change compared to p

  20. Slide 20: LAVA-1266 Targeting CD123 for Hematologic Malignancies

    Gammabody Designed to Activate V2 T Cells by Targeting CD123 for the Treatment of Hematologic Malignancies LAVA-1266

  21. Slide 21: Relative abundance of Vδ2 T cells in AML suggests an attractive target

    21 Relative abundance of V2 T cells in AML suggests this disease could be an attractive target for Gammabody therapies Estimated new diagnoses in US in 2024: 62,7701 Estimated Deaths in US in 2024: 23,6701 LAVA-1266 induced preferential lysis of CD123-expressing tumor cells while relatively sparing

  22. Slide 22: LAVA-1266: CD123-Targeting Bispecific Vδ2 T Cell Engager

    22 LAVA-1266: CD123-Targeting Bispecific V2 T Cell Engager LAVA Therapeutics, data on file • pM potency and activity at low effector to target cell ratios • Increased survival in AML xenograft model • No co-activation of immunosuppressive regulatory T cells • Does not interfere with IL-3 induced pr

  23. Slide 23: Strategic Partnerships

    Strategic Partnerships

  24. Slide 24: PF-08046052 for Solid Tumors: Phase 1 Underway

    24 Designed to induce preferential lysis of EGFR-expressing tumor cells while relatively sparing EGFR-expressing normal cells $50 million upfront received with the signing, Sept 2022 Received $7 million Phase 1 enrollment milestone, March 2024 Phase 1 Clinical Trial (NCT05983133) initiated in Q4 202

  25. Slide 25: PF-08046052 – EGFR-Targeting Gammabody

    25 PF-08046052 – EGFR-Targeting Gammabody King L, et al. Cancer Immunol Res 2023 LAVA Therapeutics, data on file Patient derived tumor tissue Patient derived non-tumor tissue

  26. Slide 26: Johnson & Johnson Innovative Medicine Collaboration: Lead Candidate Selected

    26 Undisclosed tumor associated antigen Upfront payment received in July 2023 LAVA is eligible to receive development, regulatory and commercialization milestone payments and royalties Product candidate onboarded June 2023 Johnson & Johnson Innovative Medicine Collaboration: Lead Candidate Selected

  27. Slide 27: Investment Highlights

    27 Potential first-in-class Platform maximizing the unique anticancer potential of Gamma-Delta T cells1 Engineered to selectively activate V2 T cells upon cross-linking with tumor-associated antigen Designed to drive larger therapeutic window with low incidence of high-grade CRS and limited on-targ

  28. Slide 28: www.lavatherapeutics.com [email protected]

    www.lavatherapeutics.com [email protected] Gamma-delta T cell engagers for next-generation cancer therapeutics

LAVA Therapeutics — Investor Presentation (June 2024) on 6ix